Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Illinois
Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 84 Florida 69 Colorado 41 Texas 40 Massachusetts 38
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer3 Olema Pharmaceuticals, Inc.2 Hoffmann-La Roche2 Merck Sharp & Dohme LLC2 858 Therapeutics, Inc.1
State
California84 Florida69 Colorado41 Texas40 Massachusetts38
All 47 states
Target enrolment
to

Trials with a site in Illinois

29 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
Genentech, Inc.
Phase 1/2
285
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maine
2025-10-07
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
Pfizer
Phase 3
400
Arizona, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2025-08-05
Recruiting
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Recruiting
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
DrugsRetifanlimab·Cyclophosphamide
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Recruiting
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Guardant Health, Inc.
Observational
470
Illinois
2023-10-25
Recruiting
Carevive Systems, Inc.
Observational
25
Connecticut, Illinois, North Carolina, Ohio
2023-07-19
Active, closed
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease
Intuitive Surgical
Not applicable
204
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2023-05-08
Active, closed
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
DrugsKeytruda·Pembrolizumab
IDEAYA Biosciences
Phase 1
216
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-04-18
Active, closed
Pfizer
Phase 1/2
20
California, Florida, Illinois, Massachusetts, Missouri
2023-03-01
Active, closed
Pfizer
Phase 1/2
37
California, Florida, Illinois, Missouri, Texas, Washington
2023-02-23
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Recruiting
Orano Med Theranostics, SAS
Phase 1
48
Illinois, Iowa, Kentucky, Maryland, Nebraska, Pennsylvania
2022-12-22
Active, closed
Celcuity Inc
Phase 3
701
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-12-08
Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer
Day One Biopharmaceuticals, Inc.
Phase 1/2
360
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2022-08-15
Recruiting
Relay Therapeutics, Inc.
Phase 1
930
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts
2021-12-08
Active, closed
Tolmar Inc.
Phase 3
250
California, Colorado, Illinois, Kentucky, Maryland, Nebraska, New York, Ohio
2021-07-01
Active, closed
Breast Cancer Index (BCI) Registry
NCT04875351Breast Cancer
Biotheranostics, Inc.
Observational
3,465
Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, New York
2021-04-14
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
California, Colorado, Illinois, Michigan, New York, North Carolina, Tennessee
2020-07-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-12-27
Active, closed
Hoffmann-La Roche
Phase 2
534
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2015-11-19
Active, closed
AstraZeneca
Phase 3
736
Arizona, California, Connecticut, Florida, Illinois, Maryland, Michigan, Missouri
2005-02-13
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Illinois that also match the filters currently applied.

How many clinical trials are recruiting in Illinois?

16 of the 29 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Illinois), 29 studies
PhaseStudiesRecruitingShare
Phase 39431%
Phase 1/28427.6%
Observational5417.2%
Phase 13210.3%
Phase 23210.3%
Not applicable103.4%

Most active sponsors

Lead sponsors with the most studies (Illinois)
Lead sponsorStudiesRecruiting
Pfizer31
Hoffmann-La Roche21
Merck Sharp & Dohme LLC21
Olema Pharmaceuticals, Inc.21
858 Therapeutics, Inc.11
AstraZeneca10
Biotheranostics, Inc.10
BriaCell Therapeutics Corporation11
Carevive Systems, Inc.11
Celcuity Inc10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.